Breast cancer stem cells: obstacles to therapy
- PMID: 22554712
- DOI: 10.1016/j.canlet.2012.04.023
Breast cancer stem cells: obstacles to therapy
Abstract
Only a fraction of the cells in a breast tumour are able to seed new tumour growth. These so-called breast cancer stem cells (bCSCs) are characterised by a number of discrete functional properties, some of which impact on therapeutic strategies aimed at eliminating these cells from tumours. Here we discuss how recent experimental evidence indicates that phenotypic plasticity is a central feature of tumour cell heterogeneity and drug resistance, traits that must be overcome in order to efficiently target bCSCs as a therapy for breast cancer. We propose that a better understanding of this fundamental property of breast cancer stem cells, over and above their identification in tumours, is a priority for improvement of patient survival.
Keywords: Breast; Cancer stem cells; EMT; Plasticity.
Crown Copyright © 2012. Published by Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
EMT in breast cancer stem cell generation.Cancer Lett. 2013 Sep 10;338(1):63-8. doi: 10.1016/j.canlet.2012.05.014. Epub 2012 May 22. Cancer Lett. 2013. PMID: 22634497 Review.
-
Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.Cancer Treat Rev. 2014 Apr;40(3):341-8. doi: 10.1016/j.ctrv.2013.09.008. Epub 2013 Sep 15. Cancer Treat Rev. 2014. PMID: 24090504 Review.
-
Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance.Cancer Lett. 2013 Nov 28;341(1):56-62. doi: 10.1016/j.canlet.2013.06.003. Epub 2013 Jul 2. Cancer Lett. 2013. PMID: 23830804 Review.
-
Modeling of Cancer Stem Cell State Transitions Predicts Therapeutic Response.PLoS One. 2015 Sep 23;10(9):e0135797. doi: 10.1371/journal.pone.0135797. eCollection 2015. PLoS One. 2015. PMID: 26397099 Free PMC article.
-
Breast cancer stem cells: current advances and clinical implications.Methods Mol Biol. 2015;1293:1-49. doi: 10.1007/978-1-4939-2519-3_1. Methods Mol Biol. 2015. PMID: 26040679 Review.
Cited by
-
Exploring the modulation of MLH1 and MSH2 gene expression in hesperetin-treated breast cancer cells (BT-474).J Adv Pharm Technol Res. 2024 Jan-Mar;15(1):43-48. doi: 10.4103/japtr.japtr_279_23. Epub 2024 Jan 15. J Adv Pharm Technol Res. 2024. PMID: 38389973 Free PMC article.
-
DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm.PLoS One. 2014 Jan 21;9(1):e85821. doi: 10.1371/journal.pone.0085821. eCollection 2014. PLoS One. 2014. PMID: 24465725 Free PMC article.
-
Targeting aberrant expression of Notch-1 in ALDH+ cancer stem cells in breast cancer.Mol Carcinog. 2017 Mar;56(3):1127-1136. doi: 10.1002/mc.22579. Epub 2016 Nov 5. Mol Carcinog. 2017. PMID: 27753148 Free PMC article.
-
Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer.Oncotarget. 2016 Aug 16;7(33):53137-53152. doi: 10.18632/oncotarget.10614. Oncotarget. 2016. PMID: 27447971 Free PMC article.
-
Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance.Cancers (Basel). 2018 Aug 18;10(8):274. doi: 10.3390/cancers10080274. Cancers (Basel). 2018. PMID: 30126203 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases